CRESCENT BIOPHARMA, INC. Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted
CRESCENT BIOPHARMA, INC. (CBIO) reported Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted of -$2.15 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes
us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted · last filed 2026-07-30
- CRESCENT BIOPHARMA, INC. undistributed earnings (loss) allocated to participating securities, diluted for the quarter ending 2026-06-30 was -$2.15M.
- CRESCENT BIOPHARMA, INC. undistributed earnings (loss) allocated to participating securities, diluted for the quarter ending 2026-03-31 was -$2.02M.
- CRESCENT BIOPHARMA, INC. undistributed earnings (loss) allocated to participating securities, diluted for the quarter ending 2025-12-31 was -$11.34M.
- CRESCENT BIOPHARMA, INC. undistributed earnings (loss) allocated to participating securities, diluted for the quarter ending 2025-09-30 was -$3.66M.
- CRESCENT BIOPHARMA, INC. undistributed earnings (loss) allocated to participating securities, diluted for fiscal 2025 was -$20.50M.
| Period end | Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted 3 month | Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted 6 month | Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted 9 month | Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.15M 10-Q · filed 2026-07-30 | -$4.17M 10-Q · filed 2026-07-30 | -$15.51M derived: sum of 3 quarters · filed 2026-07-30 | -$19.17M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | -$2.02M 10-Q · filed 2026-04-29 | -$13.36M derived: sum of 2 quarters · filed 2026-04-29 | -$17.02M derived: sum of 3 quarters · filed 2026-04-29 | -$19.81M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | -$11.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$15.00M derived: sum of 2 quarters · filed 2026-02-26 | -$17.79M derived: sum of 3 quarters · filed 2026-07-30 | -$20.50M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$3.66M 10-Q · filed 2025-11-06 | -$6.45M derived: sum of 2 quarters · filed 2026-07-30 | -$9.15M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | -$2.79M 10-Q · filed 2026-07-30 | -$4.03M 10-Q · filed 2026-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |